THE EFFICACY OF AMBULATORY ACL RECONSTRUCTION UTILIZING INTRAOPERATIVE LOCAL ANALGESIA AND POST-OPERATIVE ORAL PAIN MEDICATION 615

1997 ◽  
Vol 29 (Supplement) ◽  
pp. 107
Author(s):  
E. R. Aronowitz ◽  
F. A. Kleinbart
Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Bastiaan C. ter Meulen ◽  
Johanna M. van Dongen ◽  
Marinus van der Vegt ◽  
Henry C. Weinstein ◽  
Raymond W. J. G. Ostelo

Abstract Background Transforaminal epidural injections with steroids (TESI) are used increasingly for patients with sciatica. However, their safety, effectiveness, and cost-effectiveness are still a matter of debate. This a priori statistical analysis plan describes the methodology of the analysis for the STAR trial that assesses the (cost-)effectiveness of TESI during the acute stage of sciatica (< 8 weeks). Methods The STAR trial is a multicentre, randomized controlled, prospective trial (RCT) investigating the (cost-)effectiveness of TESI by making a three-group comparison among patients with acute sciatica due to a herniated lumbar disc (< 8 weeks): (1) TESI combined with levobupivacaine added to oral pain medication (intervention group 1) versus oral pain medication alone (control group), (2) intervention group 1 versus transforaminal epidural injection with levobupivacaine and saline solution added to oral pain medication (intervention group 2), and (3) intervention group 2 versus control group. Co-primary outcomes were physical functioning (Roland Morris Disability Questionnaire), pain intensity (10-point numerical rating scale), and global perceived recovery (7-point Likert scale, dichotomized into ‘recovered’ and ‘not recovered’). For all three comparisons, we defined the following minimal clinically relevant between-group differences: two points for pain intensity (range 0–10), four points for physical functioning (range 0–24) and a 20% difference in recovery rate. Secondary outcomes are health-related quality of life (EQ-5D-5L) and patient satisfaction (7-point Likert scale) and surgery rate. We also collected resource use data to perform an economic evaluation. Analyses will be conducted by intention-to-treat with p < 0.05 (two-tailed) for all three comparisons. Effects will be estimated using mixed models by maximum likelihood. For each comparison, mean differences, or difference in proportions, between groups will be tested per time point and an overall mean difference, or difference in proportions, between groups during the complete duration of follow-up (6 months) will be estimated. In the economic evaluation, Multivariate Imputation by Chained Equations will be used to handle missing data. Cost and effect differences will be estimated using seemingly unrelated regression, and uncertainty will be estimated using bootstrapping techniques. Discussion This statistical analysis plan provides detailed information on the intended analysis of the STAR trial, which aims to deliver evidence about the (cost-)effectiveness of TESI during the acute phase of sciatica (< 8 weeks). Trial registration Dutch National trial register NTR4457 (6 March 2014)


2018 ◽  
Vol 99 (8) ◽  
pp. 1609-1622.e10 ◽  
Author(s):  
Bionka M. Huisstede ◽  
Manon S. Randsdorp ◽  
Janneke van den Brink ◽  
Thierry P.C. Franke ◽  
Bart W. Koes ◽  
...  

2018 ◽  
Vol 159 (5) ◽  
pp. 835-842 ◽  
Author(s):  
Michael D. Olson ◽  
Eric J. Moore ◽  
Daniel L. Price

Objective To determine whether liposomal bupivacaine (Exparel) is safe and effective in the management of posttonsillectomy pain among adult patients. Study Design A prospective single-blind randomized controlled trial. Setting An academic quaternary care center (Mayo Clinic, Rochester, Minnesota). Subjects and Methods From May 2015 to December 2016, 39 patients were randomized to receive oral pain medication and 8 mL of injected liposomal bupivacaine or oral pain medication alone for treatment of their posttonsillectomy pain. Visual analog scale pain intensity scores, oral pain medication usage, liquid oral intake, and complications were recorded for 2 weeks after the procedure. Results Thirty-nine patients were randomized, with 17 patients in the liposomal bupivacaine group and 22 in the control group. Fifteen patients in the liposomal bupivacaine group and 18 patients in the control group completed the study. Pain intensity score on postoperative day 1 ( P = .043) proved to be the only statistically significant result, with no difference noted in pain scores on postoperative days 2 to 14. There was no difference in pain medication usage, liquid oral intake, postoperative hemorrhage, or adverse events between groups. Conclusions The injection of liposomal bupivacaine in the posttonsillectomy wound bed demonstrates improved pain intensity scores for the first 24 hours after surgery with no adverse complications noted in comparison with patients who did not receive the injection. Given the limited pain reduction and increased cost, use of liposomal bupivacaine in adult tonsillectomy patients appears to have minimal indication for use.


2014 ◽  
Vol 145 (2) ◽  
pp. 141-149 ◽  
Author(s):  
Shauna Tanner ◽  
Martha Wells ◽  
Mark Scarbecz ◽  
Billy W. McCann

2005 ◽  
Vol 30 (2) ◽  
pp. 134-139 ◽  
Author(s):  
S GOODMAN ◽  
A DRACHENBERG ◽  
S JOHNSON ◽  
M NEGRON ◽  
S KIMLO ◽  
...  

2001 ◽  
Vol 94 (1A) ◽  
pp. NA-NA ◽  
Author(s):  
S. R. Goodman ◽  
A. M. Drachenberg ◽  
S. A. Johnson ◽  
S. H. Kim-Lo ◽  
R. M. Smiley

Sign in / Sign up

Export Citation Format

Share Document